Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares IssuedShort-Term Debt repayments
Ratios

BeOne Medicines (BEIGF) Leases (2017 - 2025)

BeOne Medicines (BEIGF) has disclosed Leases for 9 consecutive years, with $148.2 million as the latest value for Q4 2025.

  • Quarterly Leases rose 6.37% to $148.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $148.2 million through Dec 2025, up 6.37% year-over-year, with the annual reading at $148.2 million for FY2025, 6.37% up from the prior year.
  • Leases for Q4 2025 was $148.2 million at BeOne Medicines, up from $140.2 million in the prior quarter.
  • The five-year high for Leases was $148.2 million in Q4 2025, with the low at $86.9 million in Q1 2021.
  • Average Leases over 5 years is $113.5 million, with a median of $109.5 million recorded in 2022.
  • The sharpest move saw Leases decreased 19.49% in 2024, then skyrocketed 66.86% in 2025.
  • Over 5 years, Leases stood at $117.4 million in 2021, then decreased by 6.36% to $110.0 million in 2022, then fell by 13.42% to $95.2 million in 2023, then surged by 46.32% to $139.3 million in 2024, then increased by 6.37% to $148.2 million in 2025.
  • According to Business Quant data, Leases over the past three periods came in at $148.2 million, $140.2 million, and $145.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.